Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
6 June 2018
|
| In: |
Annals of oncology
Year: 2018, Jahrgang: 29, Heft: 8, Pages: 1763-1770 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdy201 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdy201 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0923753419341225 
|
| Verfasserangaben: | D.A. Yardley, R. Coleman, P. Conte, J. Cortes, A. Brufsky, M. Shtivelband, R. Young, C. Bengala, H. Ali, J. Eakel, A. Schneeweiss, L. de la Cruz-Merino, S. Wilks, J. O’Shaughnessy, S. Glück, H. Li, J. Miller, D. Barton & N. Harbeck |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1695641698 | ||
| 003 | DE-627 | ||
| 005 | 20220818051303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200422s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdy201 |2 doi | |
| 035 | |a (DE-627)1695641698 | ||
| 035 | |a (DE-599)KXP1695641698 | ||
| 035 | |a (OCoLC)1341316019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Yardley, Denise |e VerfasserIn |0 (DE-588)1208800442 |0 (DE-627)1695643062 |4 aut | |
| 245 | 1 | 0 | |a Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer |b results from the tnAcity trial |c D.A. Yardley, R. Coleman, P. Conte, J. Cortes, A. Brufsky, M. Shtivelband, R. Young, C. Bengala, H. Ali, J. Eakel, A. Schneeweiss, L. de la Cruz-Merino, S. Wilks, J. O’Shaughnessy, S. Glück, H. Li, J. Miller, D. Barton & N. Harbeck |
| 264 | 1 | |c 6 June 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel erscheint "nab" klein geschrieben und schräg gestellt | ||
| 500 | |a Gesehen am 22.04.2020 | ||
| 520 | |a Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC. - Patients and methods - Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1 : 1 : 1) nab-P 125mg/m2 plus C AUC 2, nab-P 125mg/m2 plus G 1000mg/m2, or G 1000mg/m2 plus C AUC 2, all on days 1, 8 q3w. Phase II primary end point: investigator-assessed progression-free survival (PFS); secondary end points included overall response rate (ORR), overall survival (OS), percentage of patients initiating cycle 6 with doublet therapy, and safety. - Results - In total, 191 patients were enrolled (nab-P/C, n=64; nab-P/G, n=61; G/C, n=66). PFS was significantly longer with nab-P/C versus nab-P/G [median, 8.3 versus 5.5months; hazard ratio (HR), 0.59 [95% CI, 0.38-0.92]; P=0.02] or G/C (median, 8.3 versus 6.0months; HR, 0.58 [95% CI, 0.37-0.90]; P=0.02). OS was numerically longer with nab-P/C versus nab-P/G (median, 16.8 versus 12.1months; HR, 0.73 [95% CI, 0.47-1.13]; P=0.16) or G/C (median, 16.8 versus 12.6months; HR, 0.80 [95% CI, 0.52-1.22]; P=0.29). ORR was 73%, 39%, and 44%, respectively. In the nab-P/C, nab-P/G, and G/C groups, 64%, 56%, and 50% of patients initiated cycle 6 with a doublet. Grade ≥3 adverse events were mainly hematologic. | ||
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a gemcitabine | |
| 650 | 4 | |a nab-paclitaxel | |
| 650 | 4 | |a triple-negative breast cancer | |
| 700 | 1 | |a Coleman, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Conte, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cortes, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brufsky, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shtivelband, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Young, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bengala, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ali, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eakel, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a de la Cruz-Merino, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wilks, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a O’Shaughnessy, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glück, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Li, H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Miller, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Barton, D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harbeck, N. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 29(2018), 8, Seite 1763-1770 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer results from the tnAcity trial |
| 773 | 1 | 8 | |g volume:29 |g year:2018 |g number:8 |g pages:1763-1770 |g extent:8 |a Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer results from the tnAcity trial |
| 856 | 4 | 0 | |u https://doi.org/10.1093/annonc/mdy201 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0923753419341225 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200422 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |e 910000PS109972554 |e 910400PS109972554 |k 0/910000/ |k 1/910000/910400/ |p 11 | ||
| 999 | |a KXP-PPN1695641698 |e 3630012248 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"6 June 2018","dateIssuedKey":"2018"}],"person":[{"family":"Yardley","given":"Denise","display":"Yardley, Denise","role":"aut"},{"role":"aut","display":"Coleman, R.","family":"Coleman","given":"R."},{"given":"P.","family":"Conte","display":"Conte, P.","role":"aut"},{"given":"J.","family":"Cortes","display":"Cortes, J.","role":"aut"},{"role":"aut","display":"Brufsky, A.","given":"A.","family":"Brufsky"},{"display":"Shtivelband, M.","family":"Shtivelband","given":"M.","role":"aut"},{"given":"R.","family":"Young","display":"Young, R.","role":"aut"},{"family":"Bengala","given":"C.","display":"Bengala, C.","role":"aut"},{"role":"aut","given":"H.","family":"Ali","display":"Ali, H."},{"role":"aut","display":"Eakel, J.","given":"J.","family":"Eakel"},{"display":"Schneeweiss, Andreas","family":"Schneeweiss","given":"Andreas","role":"aut"},{"display":"de la Cruz-Merino, L.","family":"de la Cruz-Merino","given":"L.","role":"aut"},{"given":"S.","family":"Wilks","display":"Wilks, S.","role":"aut"},{"display":"O’Shaughnessy, J.","given":"J.","family":"O’Shaughnessy","role":"aut"},{"family":"Glück","given":"S.","display":"Glück, S.","role":"aut"},{"family":"Li","given":"H.","display":"Li, H.","role":"aut"},{"given":"J.","family":"Miller","display":"Miller, J.","role":"aut"},{"given":"D.","family":"Barton","display":"Barton, D.","role":"aut"},{"role":"aut","display":"Harbeck, N.","given":"N.","family":"Harbeck"}],"title":[{"title":"Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer","subtitle":"results from the tnAcity trial","title_sort":"Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer"}],"note":["Im Titel erscheint \"nab\" klein geschrieben und schräg gestellt","Gesehen am 22.04.2020"],"relHost":[{"id":{"eki":["320428796"],"issn":["1569-8041"],"zdb":["2003498-2"]},"recId":"320428796","physDesc":[{"extent":"Online-Ressource"}],"disp":"Nab-paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer results from the tnAcity trialAnnals of oncology","part":{"volume":"29","pages":"1763-1770","extent":"8","year":"2018","issue":"8","text":"29(2018), 8, Seite 1763-1770"},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"language":["eng"],"title":[{"title":"Annals of oncology","title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology"}],"pubHistory":["1.1990 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"name":{"displayForm":["D.A. Yardley, R. Coleman, P. Conte, J. Cortes, A. Brufsky, M. Shtivelband, R. Young, C. Bengala, H. Ali, J. Eakel, A. Schneeweiss, L. de la Cruz-Merino, S. Wilks, J. O’Shaughnessy, S. Glück, H. Li, J. Miller, D. Barton & N. Harbeck"]},"recId":"1695641698","id":{"doi":["10.1093/annonc/mdy201"],"eki":["1695641698"]},"language":["eng"],"physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a YARDLEYDENNABPACLITA6201 | ||